MyMD Pharma to present ‘statistically’ significant Phase 2 data for MYMD-1

MyMD Pharmaceuticals, announced that it plans to share information on the Company and its product pipeline, including an update on recent positive phase 2 study results for MYMD-1 in sarcopenia, at the upcoming BioFuture 2023 Meeting. MyMD recently announced positive topline Phase 2 study results in participants with sarcopenia/frailty which showed MYMD-1 demonstrated statistical significance in reducing serum levels of TNF-a, IL-6 and sTNFR1, biomarkers common to a number of chronic inflammatory diseases, and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment. New key findings from the Phase 2 study showed that cohort 4 showed a reduction in TNF-a, a key cytokine, across 28 days versus placebo. “The scientific data clearly indicate statistical significance across 28 days at the high dose group and we are extremely excited about the completion of the phase 2 clinical trial,” said Dr. Chris Chapman, MD, president, director, and chief medical officer at MyMD Pharmaceuticals. Continued Dr. Chapman, “We are pleased to share information about our company and pipeline at BioFuture 2023, particularly related to our lead candidate and next generation TNF-a inhibitor, MYMD-1, which we believe is showing tremendous promise in inflammatory diseases. Its potential to ease the burden of these diseases, which affect millions of patients, caregivers and their healthcare professionals, is what compels us to continue this important research.” The Company will present the clinical safety report to the FDA with plans to seek future guidance for a Phase 3 clinical trial in sarcopenia. If approved, MYMD-1 has the potential to be the first drug approved by FDA for the condition, an age-related decline in muscle mass and physical function which leads to greater risk of hospitalization, disability, and death.